teva report adjust dilut ep revenu compar
street estim respect guidanc essenti reflect
ebitda revenu stabil minimum said question qualiti
stabil instanc guidanc reflect impact key gener launch
 nuvar restasi reflect moder eros copaxon beyond
could easili envis return top-lin pressur copaxon competit
limit ajovi contribut vein current ebitda multipl near
strike us bit rich highli lever compani attempt drive long-term
ebitda stabil back oper effici reiter neutral rate
rais pt multipl recoveri justifi potenti
pragmat punit resolut opioid-rel case
manag guid stabil gener may littl aggress
north america gener sale total versu note
gener segment also includ biosimilar guidanc reflect contribut
key complex gener albeit risk-adjust name launch nuvar
restasi gener regard nuvar wonder big contributor nuvar
given longer first-to-market opportun given amneal
overweight launch late
austedo sale total sale teva guid
sale around number believ achiev given
austedo one two fda-approv treatment tardiv dyskinesia td space
still character rel low diagnosi rate therefor low penetr
inhibitor beyond td manag tout studi tourett syndrom
puzzl context indic competitor product
mechan action fail studi overal though believ visibl
signific austedo sale growth high confid footprint
 neurosci segment grow absenc austedo label expans
given continu eros copaxon ajovi disappoint
ajovi sale guidanc impli growth versu
aggress manag tout commerci avail auto-injector form
potenti drive inflect growth trajectori volum howev
see auto-injector transform particularli given realiti amgen
raymond lilli particularli lilli contract aggress payer
aimovig emgal respect
risk includ copaxon competit gener price risk
teva leader gener neurology-focus drug
ev/ebitda assum
cash debt
debt total capit
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu psc consensu estim
consensu estim
compani report factset psc research
compani report factset psc research
page
million except per share itemsactualspsc estimatesstreet estimatesnorth america market non-cor except per exhibit
note prior estim comparison may applic due psc updat report line item
consensu estim
includ correct report revenu isra distribut busi onward correct also deduct cost sale relat isra distribut activ
compani report factset psc estim
rais pt teva
pt base ebitda multipl
ebitda estim given fact retail gener
price environ continu look less bad visibl moder price
eros given austedo continu track nice along view improv
visibl pragmat punit resolut opioid-rel litig recent
multipl expans teva inde warrant said struggl envis top-lin
stabil beyond vein question extent recent multipl expans
put anoth way limit extent teva continu drive ebitda stabil
current rate overweight price target base
ep disc risk includ price competit risk gener
page
million except per america market non-cor consensu incom expens net share consensu teva quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
includ correct report revenu isra distribut busi onward correct also deduct cost sale relat isra distribut activ
teva alter revenu report methodolog result histor may reflect psc estim
includ sale teva proair ag sale ag includ gener segment
proprietari piper sandler februari
current disclosur inform compani found http //www pipersandl com/researchdisclosur
